Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies

Objective: Chimeric antigen receptor-modified T (CAR-T) cells have shown impressive results against relapsed/refractory B cell malignancies. However, the traditional manufacture of CAR-T cells requires leukapheresis to isolate large amounts of peripheral blood T cells, thus making some patients inel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lu Han, Jian Zhou, Linlin Li, Keshu Zhou, Lingdi Zhao, Xinghu Zhu, Qingsong Yin, Yufu Li, Hongqin You, Jishuai Zhang, Yongping Song, Quanli Gao
Formato: article
Lenguaje:EN
Publicado: China Anti-Cancer Association 2021
Materias:
Acceso en línea:https://doaj.org/article/b31ae4dc1bc947628b4a687150159dd3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!